|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Allison KH, Hammond ME, Dowsett M,
McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR,
Chavez-MacGregor M, Perlmutter J, et al: Estrogen and progesterone
receptor testing in breast cancer: ASCO/CAP guideline update. J
Clin Oncol. 38:1346–1366. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wolff AC, Hammond ME, Allison KH, Harvey
BE, Mangu PB, Bartlett JM, Bilous M, Ellis IO, Fitzgibbons P, Hanna
W, et al: Human epidermal growth factor receptor 2 testing in
breast cancer: American society of clinical oncology/college of
american pathologists clinical practice guideline focused update. J
Clin Oncol. 36:2105–2122. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Voduc KD, Cheang MC, Tyldesley S, Gelmon
K, Nielsen TO and Kennecke H: Breast cancer subtypes and the risk
of local and regional relapse. J Clin Oncol. 28:1684–1691. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tong CW, Wu M, Cho WC and To KK: Recent
advances in the treatment of breast cancer. Front Oncol. 8:2272018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Falzone L, Salomone S and Libra M:
Evolution of cancer pharmacological treatments at the turn of the
third millennium. Front Pharmacol. 9:13002018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Samaan TM, Samec M, Liskova A, Kubatka P
and Büsselberg D: Paclitaxel's mechanistic and clinical effects on
breast cancer. Biomolecules. 9:7892019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Weaver BA: How taxol/paclitaxel kills
cancer cells. Mol Biol Cell. 25:2677–2681. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rowinsky EK, Cazenave LA and Donehower RC:
Taxol: A novel investigational antimicrotubule agent. J Natl Cancer
Inst. 82:1247–1259. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Weaver BA and Cleveland DW: Decoding the
links between mitosis, cancer, and chemotherapy: The mitotic
checkpoint, adaptation, and cell death. Cancer Cell. 8:7–12. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nezi L and Musacchio A: Sister chromatid
tension and the spindle assembly checkpoint. Curr Opin Cell Biol.
21:785–795. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Raab M, Kobayashi NF, Becker S,
Kurunci-Csacsko E, Krämer A, Strebhardt K and Sanhaji M: Boosting
the apoptotic response of high-grade serous ovarian cancers with
CCNE1 amplification to paclitaxel in vitro by targeting APC/C and
the pro-survival protein MCL-1. Int J Cancer. 146:1086–1098. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Falzone L, Scandurra G, Lombardo V,
Gattuso G, Lavoro A, Distefano AB, Scibilia G and Scollo P: A
multidisciplinary approach remains the best strategy to improve and
strengthen the management of ovarian cancer (Review). Int J Oncol.
59:2021. View Article : Google Scholar
|
|
14
|
Falchook G, Coleman RL, Roszak A, Behbakht
K, Matulonis U, Ray-Coquard I, Sawrycki P, Duska LR, Tew W,
Ghamande S, et al: Alisertib in combination with weekly paclitaxel
in patients with advanced breast cancer or recurrent ovarian
cancer: A randomized clinical trial. JAMA Oncol. 5:e1837732019.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhu L and Chen L: Progress in research on
paclitaxel and tumor immunotherapy. Cell Mol Biol Lett. 24:402019.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Němcová-Fürstová V, Kopperová D,
Balušíková K, Ehrlichová M, Brynychová V, Václavíková R, Daniel P,
Souček P and Kovář J: Characterization of acquired paclitaxel
resistance of breast cancer cells and involvement of ABC
transporters. Toxicol Appl Pharmacol. 310:215–228. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang N, Wang C, Wang J, Wang Z, Huang D,
Yan M, Kamran M, Liu Q and Xu B: Aurora kinase A stabilizes FOXM1
to enhance paclitaxel resistance in triple-negative breast cancer.
J Cell Mol Med. 23:6442–6453. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang Y, Chen G, Wang Y, He R, Du J, Jiao
X and Tai Q: Inhibition of microRNA-16 facilitates the paclitaxel
resistance by targeting IKBKB via NF-κB signaling pathway in
hepatocellular carcinoma. Biochem Biophys Res Commun.
503:1035–1041. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Karin M and Ben-Neriah Y: Phosphorylation
meets ubiquitination: The control of NF-[kappa]B activity. Annu Rev
Immunol. 18:621–663. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Courtois G and Smahi A: NF-κB-related
genetic diseases. Cell Death Differ. 13:843–851. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wendt MK, Taylor MA, Schiemann BJ and
Schiemann WP: Down-regulation of epithelial cadherin is required to
initiate metastatic outgrowth of breast cancer. Mol Biol Cell.
22:2423–2435. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liao J, Yang Z, Carter-Cooper B, Chang ET,
Choi EY, Kallakury B, Liu X, Lapidus RG, Cullen KJ and Dan H:
Suppression of migration, invasion, and metastasis of
cisplatin-resistant head and neck squamous cell carcinoma through
IKKβ inhibition. Clin Exp Metastasis. 37:283–292. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM
and Zhou BP: Stabilization of snail by NF-kappaB is required for
inflammation-induced cell migration and invasion. Cancer Cell.
15:416–428. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu ST, Sun GH, Hsu CY, Huang CS, Wu YH,
Wang HH and Sun KH: Tumor necrosis factor-α induces
epithelial-mesenchymal transition of renal cell carcinoma cells via
a nuclear factor kappa B-independent mechanism. Exp Biol Med
(Maywood). 236:1022–1029. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Geiger TR and Peeper DS: Metastasis
mechanisms. Biochim Biophys Acta. 1796:293–308. 2009.PubMed/NCBI
|
|
27
|
Craene BD and Berx G: Regulatory networks
defining EMT during cancer initiation and progression. Nat Rev
Cancer. 13:97–110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huber MA, Azoitei N, Baumann B, Grünert S,
Sommer A, Pehamberger H, Kraut N, Beug H and Wirth T: NF-κB is
essential for epithelial-mesenchymal transition and metastasis in a
model of breast cancer progression. J Clin Invest. 114:569–581.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Esparza-Lopez J, Alvarado-Munoz JF,
Escobar-Arriaga E, Ulloa-Aguirre A and Ibarra-Sanchez MJ: Metformin
reverses mesenchymal phenotype of primary breast cancer cells
through STAT3/NF-κB pathways. BMC Cancer. 19:7282019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Esparza-Lopez J, Ramos-Elias PA,
Castro-Sanchez A, Rocha-Zavaleta L, Escobar-Arriaga E,
Zentella-Dehesa A, León-Rodríguez E, Medina-Franco H and
Ibarra-Sánchez MJ: Primary breast cancer cell culture yields
intra-tumor heterogeneous subpopulations expressing exclusive
patterns of receptor tyrosine kinases. BMC Cancer. 16:7402016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Navarrete-Bernal MG, Cervantes-Badillo MG,
Martinez-Herrera JF, Lara-Torres CO, Gerson-Cwilich R,
Zentella-Dehesa A, Ibarra-Sánchez MJ, Esparza-López J, Montesinos
JJ, Cortés-Morales VA, et al: Biological landscape of triple
negative breast cancers expressing CTLA-4. Front Oncol.
10:12062020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Murray RZ and Norbury C: Proteasome
inhibitors as anti-cancer agents. Anticancer Drugs. 11:407–417.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ibarra-Sanchez MJ, Wagner J, Ong MT,
Lampron C and Tremblay ML: Murine embryonic fibroblasts lacking
TC-PTP display delayed G1 phase through defective NF-kappaB
activation. Oncogene. 20:4728–4739. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen J, Tian W, He H, Chen F, Huang J,
Wang X and Chen Z: Downregulation of miR200c3p contributes to the
resistance of breast cancer cells to paclitaxel by targeting SOX2.
Oncol Rep. 40:3821–3829. 2018.PubMed/NCBI
|
|
35
|
Greenberger LM, Lothstein L, Williams SS
and Horwitz SB: Distinct P-glycoprotein precursors are overproduced
in independently isolated drug-resistant cell lines. Proc Natl Acad
Sci USA. 85:3762–3766. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mozzetti S, Ferlini C, Concolino P,
Filippetti F, Raspaglio G, Prislei S, Gallo D, Martinelli E,
Ranelletti FO, Ferrandina G and Scambia G: Class III beta-tubulin
overexpression is a prominent mechanism of paclitaxel resistance in
ovarian cancer patients. Clin Cancer Res. 11:298–305.
2005.PubMed/NCBI
|
|
37
|
Dumontet C, Isaac S, Souquet PJ,
Bejui-Thivolet F, Pacheco Y, Peloux N, Frankfurter A, Luduena R and
Perol M: Expression of class III beta tubulin in non-small cell
lung cancer is correlated with resistance to taxane chemotherapy.
Bull Cancer. 92:E25–E30. 2005.PubMed/NCBI
|
|
38
|
Li X, Lewis MT, Huang J, Gutierrez C,
Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC,
et al: Intrinsic resistance of tumorigenic breast cancer cells to
chemotherapy. J Natl Cancer Inst. 100:672–679. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ren H, Du P, Ge Z, Jin Y, Ding D, Liu X
and Zou Q: TWIST1 and BMI1 in cancer metastasis and
chemoresistance. J Cancer. 7:1074–1080. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang L, Zhang F, Cui JY, Chen L, Chen YT
and Liu BW: CAFs enhance paclitaxel resistance by inducing EMT
through the IL6/JAK2/STAT3 pathway. Oncol Rep. 39:2081–2090.
2018.PubMed/NCBI
|
|
41
|
Liao SJ, Luo J, Li D, Zhou YH, Yan B, Wei
JJ, Tu JC, Li YR, Zhang GM and Feng ZH: TGF-β1 and TNF-α
synergistically induce epithelial to mesenchymal transition of
breast cancer cells by enhancing TAK1 activation. J Cell Commun
Signal. 13:369–380. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Espinoza-Sánchez NA, Győrffy B,
Fuentes-Pananá EM and Götte M: Differential impact of classical and
non-canonical NF-κB pathway-related gene expression on the survival
of breast cancer patients. J Cancer. 10:5191–5211. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Prajoko YW and Aryandono T: Expression of
nuclear factor kappa B (NF-κB) as a predictor of poor pathologic
response to chemotherapy in patients with locally advanced breast
cancer. Asian Pac J Cancer Prev. 15:595–598. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nottingham LK, Yan CH, Yang X, Si H,
Coupar J, Bian Y, Cheng TF, Allen C, Arun P, Gius D, et al:
Aberrant IKKα and IKKβ cooperatively activate NF-κB and induce
EGFR/AP1 signaling to promote survival and migration of head and
neck cancer. Oncogene. 33:1135–1147. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Guarneri C, Bevelacqua V, Polesel J,
Falzone L, Cannavò PS, Spandidos DA, Malaponte G and Libra M: NFκB
inhibition is associated with OPN/MMP9 downregulation in cutaneous
melanoma. Oncol Rep. 37:737–746. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Li W, Li S, Yang J, Cui C, Yu M and Zhang
Y: ITGBL1 promotes EMT, invasion and migration by activating NF-κB
signaling pathway in prostate cancer. Onco Targets Ther.
12:3753–3763. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Pires BR, Mencalha AL, Ferreira GM, de
Souza WF, Morgado-Díaz JA, Maia AM, Corrêa S and Abdelhay ES:
NF-kappaB is involved in the regulation of EMT genes in breast
cancer cells. PLoS One. 12:e01696222017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Momeny M, Eyvani H, Barghi F, Ghaffari SH,
Javadikooshesh S, Jamadi RH, Esmaeili F, Alishahi Z, Zaghal A,
Bashash D, et al: Inhibition of bromodomain and extraterminal
domain reduces growth and invasive characteristics of
chemoresistant ovarian carcinoma cells. Anticancer Drugs.
29:1011–1020. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang Y, Yang B, Zhao J, Li X, Zhang L and
Zhai Z: Proteasome inhibitor
carbobenzoxy-L-Leucyl-L-Leucyl-L-Leucinal (MG132) enhances
therapeutic effect of paclitaxel on breast cancer by inhibiting
nuclear factor (NF)-κB signaling. Med Sci Monit. 24:294–304. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Abdin SM, Tolba MF, Zaher DM and Omar HA:
Nuclear factor-κB signaling inhibitors revert multidrug-resistance
in breast cancer cells. Chem Biol Interact. 340:1094502021.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Concetti J and Wilson CL: NFKB1 and
cancer: Friend or Foe? Cells. 7:1332018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kravtsova-Ivantsiv Y, Shomer I,
Cohen-Kaplan V, Snijder B, Superti-Furga G, Gonen H, Sommer T, Ziv
T, Admon A, Naroditsky I, et al: KPC1-mediated ubiquitination and
proteasomal processing of NF-κB1 p105 to p50 restricts tumor
growth. Cell. 161:333–347. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Long YM, Ye S, Rong J and Xie WR: Nuclear
factor kappa B: A marker of chemotherapy for human stage IV gastric
carcinoma. World J Gastroenterol. 14:4739–4744. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kim JH, Gupta SC, Park B, Yadav VR and
Aggarwal BB: Turmeric (Curcuma longa) inhibits inflammatory nuclear
factor (NF)-κB and NF-κB-regulated gene products and induces death
receptors leading to suppressed proliferation, induced
chemosensitization, and suppressed osteoclastogenesis. Mol Nutr
Food Res. 56:454–465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kim SH, Park HJ and Moon DO: Sulforaphane
sensitizes human breast cancer cells to paclitaxel-induced
apoptosis by downregulating the NF-κB signaling pathway. Oncol
Lett. 13:4427–4432. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Azad N, Vallyathan V, Wang L,
Tantishaiyakul V, Stehlik C, Leonard SS and Rojanasakul Y:
S-nitrosylation of Bcl-2 inhibits its ubiquitin-proteasomal
degradation. A novel antiapoptotic mechanism that suppresses
apoptosis. J Biol Chem. 281:34124–34134. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Esparza-López J, Escobar-Arriaga E,
Soto-Germes S and Ibarra-Sánchez MJ: Breast cancer intra-tumor
heterogeneity: One tumor, different entities. Rev Invest Clin.
69:66–76. 2017.PubMed/NCBI
|
|
58
|
Esparza-López J, Martinez-Aguilar JF and
Ibarra-Sánchez MJ: Deriving primary cancer cell cultures for
personalized therapy. Rev Invest Clin. 71:369–380. 2019.PubMed/NCBI
|
|
59
|
Rosenbluth JM, Schackmann RCJ, Gray GK,
Selfors LM, Li CM, Boedicker M, Kuiken HJ, Richardson A, Brock J,
Garber J, et al: Organoid cultures from normal and cancer-prone
human breast tissues preserve complex epithelial lineages. Nat
Commun. 11:17112020. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kim J, Koo BK and Knoblich JA: Human
organoids: Model systems for human biology and medicine. Nat Rev
Mol Cell Biol. 21:571–584. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Grisanzio C, Seeley A, Chang M, Collins M,
Napoli AD, Cheng SC, Percy A, Beroukhim R and Signoretti S:
Orthotopic xenografts of RCC retain histological, immunophenotypic
and genetic features of tumours in patients. J Pathol. 225:212–221.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Jager W, Moskalev I, Janssen C, Hayashi T,
Awrey S, Gust KM, So AI, Zhang K, Fazli L, Li E, et al:
Ultrasound-guided intramural inoculation of orthotopic bladder
cancer xenografts: A novel high-precision approach. PLoS One.
8:e595362013. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Murayama T and Gotoh N: Patient-derived
xenograft models of breast cancer and their application. Cells.
8:6212019. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Schmidt KF, Ziu M, Schmidt NO, Vaghasia P,
Cargioli TG, Doshi S, Albert MS, Black PM, Carroll RS and Sun Y:
Volume reconstruction techniques improve the correlation between
histological and in vivo tumor volume measurements in mouse models
of human gliomas. J Neurooncol. 68:207–215. 2004. View Article : Google Scholar : PubMed/NCBI
|
